Boston Scientific Corporation BSX

Wells Fargo has put a number on the damage Boston Scientific Corporation’s (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly $300 million in sales and about $0.13 per share in earnings. Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific to $48 from $50 […]

Oppenheimer has become considerably more cautious on Boston Scientific Corporation (NYSE:BSX), but not cautious enough to abandon its bullish rating. Analyst Suraj Kalia lowered the firm’s price target on Boston Scientific to $65 from $85 on September 21, ahead of the company’s quarterly results, while maintaining an Outperform rating. Kalia is also reducing Oppenheimer’s fiscal […]

Boston Scientific (BSX) is in focus after initiating a Class II recall of its StoneSmart Connect Console power adapters, affecting 982 units distributed across the US and multiple international markets. Against this recall backdrop, Boston Scientific’s share price has eased 1.7% over the last trading day and is down 6.2% over the past month, while the 1‑year total shareholder return has declined 54.7%, signaling fading momentum despite a small 2.9% gain on a 90‑day share price basis. Scan how...

Boston Scientific (NYSE: BSX) has started a voluntary global recall of its StoneSmart Connect Console over a power adapter safety issue. The company is informing hospitals and healthcare providers worldwide about the recall and advising on identification and return of affected units. Arthur C. Butcher, who oversees key endoscopy and urology portfolios, has notified Boston Scientific of his decision to retire. The recall of StoneSmart Connect and Arthur C. Butcher's retirement only capture...

Growth is driven by rising cardiovascular disease, telehealth adoption, and advances in wearable ECG devices, implantable monitors, AI analytics, and cloud platforms. North America leads, while Asia-Pacific is expected to grow fastest.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Remote Cardiac Monitoring Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Remote Cardiac Monitoring Mark

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

Ammonix today emerged from stealth with a new AI architecture that combines a fast, specialized System One decision-making architecture with a System Two language model for reasoning and interaction.

The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

After decades of spinoffs and separations of various parts, GE Aerospace is now trending toward integration.